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Abstract Cells are able to execute apoptosis by activat-
ing series of speciﬁc biochemical reactions. One of the
most prominent characteristics of cell death is the exter-
nalization of phosphatidylserine (PS), which in healthy
cells resides predominantly in the inner leaﬂet of the
plasma membrane. These features have made PS-exter-
nalization a well-explored phenomenon to image cell death
for diagnostic purposes. In addition, it was demonstrated
that under certain conditions viable cells express PS at their
surface such as endothelial cells of tumor blood vessels,
stressed tumor cells and hypoxic cardiomyocytes. Hence,
PS has become a potential target for therapeutic strategies
aiming at Targeted Drug Delivery. In this review we
highlight the biomarker PS and various PS-binding com-
pounds that have been employed to target PS for diagnostic
purposes. We emphasize the 35 kD human protein annexin
A5, that has been developed as a Molecular Imaging agent
to measure cell death in vitro, and non-invasively in vivo in
animal models and in patients with cardiovascular diseases
and cancer. Recently focus has shifted from diagnostic
towards therapeutic applications employing annexin A5 in
strategies to deliver drugs to cells that express PS at their
surface.
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Introduction
Scientiﬁc and technological developments of the past dec-
ade have been directed towards the unraveling of molecular
ﬁngerprints of distinct diseases in order to facilitate diag-
nosis and pharmacotherapy by Molecular Imaging (MI) and
Targeted Drug Delivery (TDD), respectively. Phosphati-
dylserine (PS) is one of the molecules that has gained
special attention as being part of a cell surface ﬁngerprint of
stressed and dying cells. PS is a negatively charged am-
inophospholipid that is present in all cells and constitutes
approximately 2–10% of total cellular lipid [1]. In addition
to a structural function PS is involved in signaling pathways
such as protein kinase C pathways [2] and in localizing
intracellular proteins to cytosolic membrane leaﬂets [3]. PS
is normally localized in membrane leaﬂets that face the
cytosol. However, certain conditions can cause transloca-
tion of PS to the outer leaﬂet of the plasma membrane where
it may initiate and participate in humoral and cellular pro-
cesses such as blood coagulation and phagocytosis. Cell
surface expression of PS has been found with aging eryth-
rocytes, activated platelets, activated macrophages, endo-
thelial cells of tumor blood vessels, apoptotic cells,
apoptotic bodies and cell derived microparticles. It is gen-
erally believed that phagocytes in healthy tissues rapidly
and efﬁciently remove PS expressing cells and cell rem-
nants. Diseased tissues on the other hand have a sustained
presence of cell surface expressed PS as a result of an
imbalance in appearance and clearance of PS expressing
cells and cell remnants. Cell surface expressed PS is
therefore a useful target for Molecular Imaging and Tar-
geted Drug Delivery (TDD) strategies. This review
addresses PS and its binding ligands with potential appli-
cations in diagnosis and treatment of a variety of diseases
including cardiovascular diseases and cancer.
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PS is ubiquitously present in prokaryotic and eukaryotic
cells and constitutes about 2–10% of total cellular lipids
depending on species and cell type. PS synthetic pathways
differ between bacteria, yeast and mammals [4]. Mamma-
lian cells synthesize PS predominantly by converting
enzymatically phosphatidylcholine (PC) and phosphati-
dylethanolamine (PE) through a serine exchange reaction.
The enzymes PS-synthase 1 (substrate PC) and PS-syn-
thase 2 (substrate PE) catalyze the conversion and are
present in the endoplasmatic reticulum (Fig. 1).
PS appears to be crucial to the cell and, as such, is
produced by different biosynthetic routes that can com-
pensate each other to maintain a certain minimal level of
PS in case one route fails [5, 6]. Cellular PS is non-ran-
domly distributed through several transport mechanisms
including vesicular transport and lipid-transfer protein
mediated lipid-exchange between juxtapositioned bilayers
[7]. Once present in the PM it is subject to the action of the
aminophospholipid transporter (APLT) which translocates
PS rapidly from the exoplasmic to the cytoplasmic leaﬂet if
PS appears in the exoplasmic leaﬂet. APLT also translo-
cates PE albeit at a lower rate [8]. The aminophospholipids
are thus moved across the bilayer against their gradient and
the energy required for translocation is derived from
hydrolysis of ATP. APLT appears to be a member of the
family of P4 type ATPases, a class of ATPases that mediate
ATP-dependently the transbilayer movement of phospho-
lipids [9]. APLT activity is present in erythrocytes, plate-
lets and nucleate cells [10]. In the latter APLT resides in
the PM and in trans-Golgi and Golgi derived secretory
vesicles. PS asymmetry, once established, is a relatively
stable steady state, and APLT activity is required again if
disturbances caused by for example membrane fusion
processes during endo- and exocytosis occur. It has been
shown that inhibition of APLT activity only results in a
slow rate of PS exposure [11] indicating that PS asymmetry
of the PM is of importance to cell homeostasis.
Cell surface expression of PS
Certain conditions may induce cells to release their PS
asymmetry of the PM. For example aging of erythrocyte,
activation of platelets and apoptosis are accompanied by a
sustained appearance of PS in the exoplasmic leaﬂet
[12, 13]. As indicated above, inhibition of APLT is insuf-
ﬁcient to cause rapid and sustained cell surface exposure of
PS. An additional mechanism is required to achieve a
steady state level of PS in the exoplasmic leaﬂet. Current
main hypothesis describes a scramblase activity to be
responsible for PS appearance at the cell surface.
Scramblase translocates phospholipids bidirectionally
over the two leaﬂets of the PM thereby collapsing PS
asymmetry. Scrambling is rapid, ATP-independent and
non-selective for phospholipid species and it causes ran-
domization of the phospholipids over the two membrane
leaﬂets. Scramblase has been demonstrated to operate in
erythrocytes [14], activated platelets [15] and apoptotic
cells [16]. Several studies have tried to identify the pro-
tein(s) that scramble the phospholipids of the PM. Isolation
and reconstitution experiments delivered the protein
phospholipid scramblase 1 (PLSCR1), which is the most
serious candidate up to now [17]. Closer inspection, how-
ever, casted doubt because cells were able to scramble PM
phospholipids in the absence of PLSCR1 [18] and six
Fig. 1 Schematic presentation of synthesis and transport of PS in
mammalian cells. PS is synthesized predominantly by PS-synthase 1
and PS-synthase 2 by converting PC and PE through a serine
exchange reaction in the endoplasmic reticulum. After synthesis PS is
non-randomly distributed by vesicle transport, membrane fusion and
exchange between juxtapositioned bilayers. PS-trafﬁcking pathways
are indicated by ‘‘dotted arrows’’. Once present in the PM PS is
subject to the action of APLT- and PLSCR-transporters. Increase of
cytosolic Ca
2?-concentration ([Ca
2?]i) inhibits APLT and activates
PLSCR. PSS, PS-synthase; LTP, lipid transfer protein; APLT,
aminophospholipid translocase; PLSCR, phosholipid scramblase;
ER, endoplasmatic reticulum; EPL, exoplasmic leaﬂet; CPL, cyto-
plasmic leaﬂet; PM, plasma membrane; PC, phosphatidylcholine; PE,
phosphatidylethanolamine; PS, phosphatidylserine
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123different cell lines showed a lack of correlation between the
level of PLSCR1 expression and the capacity to externalize
PS during apoptosis [19]. No other candidates are proposed
as yet indicating complexity of phospholipid scrambling
and, likely, diversity in scrambling mechanisms. The latter
is illustrated by the ﬁnding that platelets of a patient with
Scott syndrome fail to express PS upon Ca
2?-ionophore
treatment (a trigger for healthy platelets to expose PS)
whilst Scott B-cells normally translocate PS to the cell
surface upon execution of apoptosis [20].
Recently an alternative hypothesis was postulated that
describes PS externalization as part of membrane repair
mechanisms that start to operate during apoptosis and
involve fusion of lysosomes with PM [21]. This hypothesis
does not require the action of a scramblase protein.
Translocation of PS to the PM exoplasmic leaﬂet pro-
ceeds without compromising the barrier function of the
PM. Once in the exoplasmic leaﬂet PS may participate in a
variety of processes depending on type and localization of
the PS exposing cell. Circulating erythrocytes for example
gradually express PS during aging. PS at the erythrocyte
surface functions as an ‘eat me’ signal towards the retic-
uloendothelial system, which clears the PS tagged eryth-
rocytes from the circulation by phagocytosis [22]. Platelets
can participate in hemostatic and thrombotic processes and
while doing so can expose PS at their surface. The PS
expressing surface catalyzes coagulation reactions that
culminate in the formation of thrombin, which subse-
quently stabilizes the platelet thrombus by generation of
ﬁbrin [23]. Activated macrophages that are engaged to
engulf dying cells expose PS at their surface. Inhibition of
PS exposure greatly impairs phagocytic capacity of the
activated macrophage [24]. Vaccinia virus presents PS at
the viral membrane to activate PS dependent macropino-
cytosis with subsequent infection of the host cell [25].
Macrophages and ﬁbroblasts that are infected with Pich-
inde Virus express PS at the cell surface [26].
The most important and abundant cellular process that is
accompanied by cell surface expression of PS is apoptosis,
a biochemically regulated process of cell suicide [27].
Firstly described for apoptotic lymphocytes [13]P S
exposure is now appreciated as a ubiquitous phenomenon
of apoptosis that is independent of cell type and cell death
inducing trigger [28] and that is phylogenetically con-
served [29]. PS on the surface of an apoptotic cell is one of
the most important ‘eat me’ ﬂags that not only triggers
engulfment but also activates signaling pathways that
control cholesterol efﬂux and expression of anti- and pro-
inﬂammatory cytokines [30]. In addition, PS on the apop-
totic cell surface is involved in regulation of immune
response towards antigens of the apoptotic cell [31]. Cells
that die by executing a non-apoptotic cell death program
also activate a machinery that drives cells surface
expression of PS [32] indicating that PS expression is an
important phenomenon in dealing with cell death in the
context of the multicellular organism. Recognition and
engulfment of PS expressing cells are extremely efﬁcient in
healthy tissues, which therefore contain, if any, a low
steady state level of PS expressing cells. Pathologies can
change drastically the balance between appearance and
clearance of PS expressing cells towards a sustained
presence of PS expressing cells and cell remnants such as
apoptotic bodies and cell derived microparticles in diseased
tissue. As such surface expressed PS is potentially an
informative biomarker for diagnosing disease and evalu-
ating efﬁcacy of therapy. In addition cell surface expressed
PS may serve as a target for TDD strategies to deliver
therapeutic compounds speciﬁcally to diseased tissue.
PS binding ligands
In order to exploit fully the potential of PS as a target for
Molecular Imaging (diagnosis) and TDD (therapy) ligands
should be available that bind selectively and with high
afﬁnity to cell surface expressed PS in the complexity of
the multicellular organism. To date a variety of PS-binding
compounds have been reported in the literature including
proteins [2], peptides [33–36] and small chemical entities
[37]. As Molecular Imaging agents peptides and small
chemical compounds generally have the advantage of
being quickly and efﬁciently cleared from the blood cir-
culation. The signal to background ratio is favorably
affected by such kinetics. However, the disadvantage of
these compounds concerns their low afﬁnity for binding
PS. Proteins on the other hand can exhibit higher afﬁnities
for PS but proteins are usually cleared from the blood
circulation with slower kinetics. The next sections will
highlight in particular the proteins annexin A5, synapto-
tagmin I and lactadherin with which a body of experience
has been build about Molecular Imaging of PS expressing
cells in vivo in animal models employing a variety of
imaging modalities. To date annexin A5 is the only protein
that has been used to visualize PS expressing cells in
patients using nuclear imaging. Key characteristics of these
three proteins are summarized in Table 1.
Annexin A5
Annexin A5 was discovered as an anticoagulant protein of
vascular tissue [38]. It is a non-glycosylated single chain
protein that belongs to the annexin super-gene family. Its
polypeptide is organized in an N-terminal tail with a
C-terminal core containing four domains that form the
annexin-core, a slightly bent surface with a convex shape
that interacts with the PS containing phospholipid
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123membrane [39, 40]. PS binding of annexin A5 is Ca
2?-
dependent. Ca
2?-ions bind to the annexin core surface at
type II Ca
2?-binding sites [41] and form the prime contact
by coordinating carbonyl and carboxyl groups of the pro-
tein and phosphoryl moieties of the glycerol backbone of
membrane phospholipids [40]. The domains are composed
mainly of a-helices and the Ca
2?-binding sites protrude as
loops (Fig. 2). The overall PS binding afﬁnity arises from a
collaboration between the Ca
2?-binding sites of the four
domains with a dominant role for domain 1 [42]. The
complex structure/function relationship of annexin A5 and
PS binding has sofar prevented the generation of smaller
fragments or mimetics that interact with PS with compa-
rable binding afﬁnity. In solution annexin A5 is present as
monomer but once bound to PS-expressing membrane
three monomers build a trimer by protein–protein interac-
tion and trimers assemble in a two-dimensional lattice
covering the PS expressing surface by trimer-trimer inter-
actions [43]. The two-dimensional protein network of
annexin A5 at a PS expressing cell surface drives inter-
nalization of annexin A5 [44]. Syntaptotagmin I and
lactadherin have reported properties neither of two-
dimensional crystallisation on the phospholipid surface nor
of internalization via the PS portal of cell entry. Annexin
A5 binds PS containing membranes with a Kd in the range
of 0.1–2 nM (Table 1).
Synaptotagmin I
Synaptotagmin I is a synaptic vesicle membrane protein
with a short N-terminal intravesicular sequence, a single
transmembrane region, and a cytoplasmic region contain-
ing two domains with homology to the C2-domain of
Protein Kinase C [45–47]. It functions intracellularly as
Ca
2?-sensor to mediate synaptic vesicle fusion upon rise of
cytoplasmic Ca
2?-levels. Phospholipid binding of synapt-
otagmin I is mediated by its C2-domains which bind
preferentially the negatively charged phospholipids PS and
phosphatidylinositol [48, 49]. PS binding can be exhibited
by a single C2 domain as was shown for the ﬁrst C2
domain (C2A) that was expressed recombinantly by E. coli
[37]. The C2A-domain is composed of stable eight-stran-
ded-sandwiches with ﬂexible loops emerging from the top
and bottom [48]. These loops bind Ca
2? [50] and acquire
subsequently a positive electrostatic potential that becomes
attracted by negatively charged phospholipid membranes
(Fig. 2)[ 51]. The C2B domain can bind phospholipids
Ca
2?-independently [52]. The dissociation constant (Kd)
of synaptotagmin I binding to PS is within the 15–40
nM-range (Table 1).
Lactadherin
Lactadherin is a glycosylated protein that was ﬁrstly dis-
coveredasacomponentofmilkfatglobulemembranes[53].
It contains an EGF-like domain harbouring an RGD
sequence that mediates interaction with the integrin recep-
tors avb3/5. At the C-terminal end of the RGD-containing
EGF-like domain reside two C domains bearing homologies
with the C1 and C2 domains of blood coagulation factors V
and VIII. Lactadherin functions as bridging molecule
facilitating phagocytosis of dying cells [54, 55]. The RGD-
motif interacts with integrin receptors on the surface of
phagocytes and the C2-like domain binds in a Ca
2?-inde-
pendent manner with cell surface expressed PS [56]. The
C2-domain of lactadherin contains a b-barrel core with
Table 1 Key characteristics of the PS binding proteins annexin A5, synaptotagmin I and lactadherin
Protein MW (kD) Source PS-binding
Domain Ca
2?-required Kd (nM)
Annexin A5 36 Human, expressed in E. coli [70] Annexin core Yes 0.1–2 [108, 109]
Synaptotagmin I 65 Human, C2A domain expressed in E. coli [83] C2A-domain
a Yes 15–40 [82]
Lactadherin 47 Bovine, puriﬁed from milk [110] C2-domain
a No 3–4 [110]
a Despite similar nomenclature, the C2-domains of synaptotagmin I and lactadherin do not share sequence homology
Fig. 2 Ribbon presentations of the structures of the PS binding
domains of annexin A5, synaptotagmin I and lactadherin. The
structural data were retrieved from the Protein Data Bank (PDB)
entries 1AVR, 1BYN and 3BN6, respectively. The purple spheres
represent Ca
2?-ions
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2?-inde-
pendently with PS (Fig. 2). The C2-domain of lactadherin
shows no signiﬁcant homology with the C2A domain of
synaptotagmin I. Interestingly lactadherin binds PS in a
stereo-speciﬁc manner [57]. Stereo-speciﬁcity has not been
observed for the PS binding proteins synaptotagmin I and
annexin A5. Lactadherin binds to PS containing membranes
with a Kd ranging from 2 to 4 nM (Table 1).
Other PS binding proteins
Other PS-binding proteins that have potential to be used as
ligands for imaging PS expressing cells include T cell
immunoglobin mucins, c-carboxyglutamic acid (Gla) con-
taining proteins and antibodies directed against PS. T cell
immunoglobulin mucin 1 and 4 (TIM-1, TIM-4), both
members of the TIM-family were originally identiﬁed as a
marker of T cell subsets. TIM-proteins are transmembrane
proteins that share an immunoglobulin variable domain
containing 6 cysteines, a mucin like domain, a transmem-
brane domain and a cytoplasmic domain [58]. Both TIM-1
and TIM-4 act as a phagocyte receptor for PS expressed on
the apoptotic cell [59]. The immunoglobulin domain binds
speciﬁcally to PS with a Kd of approximately 2 nM [60].
Gla-domain containing proteins such as vitamin
K-dependent blood coagulation factors bind PS through a
Ca
2?-mediated interaction between Gla-residues and PS
[61]. Gla-domain containing proteins generally bind PS
expressing membranes with a Kd in the nM range.
Immunization procedures with PS as antigen may gen-
erate antibodies against PS [62]. However, in most cases
immunization results in the generation of antibodies that
recognize plasma proteins bound to PS. To target PS on
tumor vasculature, the murine monoclonal antibody 3G4
was generated [63]. It appeared that 3G4 does not bind PS
directly but through plasma protein 2-glycoprotein 1 that
wasboundtoPS[64].Plasmaprotein2-glycoprotein1binds
weaklytoanionicphospholipidswhereasinpresenceof3G4
its afﬁnity for anionic membranes increases signiﬁcantly.
Molecular Imaging of PS
As described above PS expressing cells and cell remnants
accumulate in diseased tissues predominantly as a result of
the activation of cell death processes and insufﬁcient
clearance of the PS expressing cells. Apoptosis is the major
process of cell death and plays a role in a wide range of
pathologies [65–69]. Therefore non-invasive and tomo-
graphic imaging of surface expressed PS has gained
interest not only in basic and translational research but also
in various clinical disciplines to support diagnosis, localize
pathological sites and assess efﬁcacy of therapy. The
availability of the PS binding ligand annexin A5 has
boosted research and development of Molecular Imaging
of PS. To date imaging studies in animal models have been
carried out predominantly with various labeled forms of
annexin A5. A number of papers have reported about the
use of a labeled fusion protein of Gluthation-S-transferase
(GST) and the C2A domain of synaptotagmin I. Lactadh-
erin is the less employed one of the three PS binding
proteins. Its use has been conﬁned to in vitro studies sofar.
Molecular Imaging of PS with Annexin A5
The recombinantly expressed human annexin A5 exhibits
PS binding properties identical to annexin A5 puriﬁed from
human tissue [70]. Availability of recombinant annexin A5
spurred synthesis of a wide range of labeled forms of
annexin A5 to accomodate PS imaging with modalities
such as optical, radionuclide and magnetic resonance
imaging [71, 72]. Annexin A5 is labeled with reporter
compounds through chemical coupling mostly to primary
amino groups of annexin A5. Since these are also present
on the surface of the annexin core amine-based coupling
may compromise the PS binding potency [73, 74]. In order
to avoid deleterious effects of coupling, annexin A5 vari-
ants have been generated for site-directed labeling at the
concave side of the molecule using thiol chemistry.
Annexin A5 variants have been generated with thiol-link-
age sites in extensions of the N-terminus [75, 76] and thiol-
linkage sites within the N-terminal tail and the concave
side of annexin A5 to which small compounds (chelators of
radionuclides [77] and ﬂuorochromes [78]) as well as
particles with diameters ranging from 10 to 100 nm (iron
oxide nanoparticles [79] and liposomes [80, 81]) have been
coupled successfully without impairing PS binding. This
so-called ‘second generation’ annexin A5 has improved
biodistribution and PS binding properties as compared to
amine-labeled wildype annexin A5.
Molecular Imaging of PS with C2A domain
of Synaptotagmin I
Synaptotagmin I is less suitable as a whole molecule for
Molecular Imaging because of its transmembrane domain.
The soluble PS binding C2A domain was expressed
recombinantly by E. coli as a fusion protein with GST.
Although the afﬁnity for binding PS is higher for C2A
(Kd = 20–40 nM) as compared to the fusion protein C2A-
GST (Kd =± 115 nM) it was decided to develop C2A-GST
as a s ligand because labeling of C2A interfered with PS
binding [82]. Labeling of GST-C2A likely occurred pre-
dominantlyatthe GSTmoiety.C2A-GSTcanbeconjugated
to ﬂuorochromes, radionuclides and superparamagnetic
iron oxide particles using random chemical linkage while
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ted chemical linkage will yield a superior PS imaging ligand
has not been reported so far.
Molecular Imaging of PS with lactadherin
For PS imaging purposes lactadherin was puriﬁed from
bovine milk [85]. To date PS imaging with lactadherin has
been limited to in vitro studies only. Lactadherin has been
coupled to ﬂuorescein isothiocyanate via random chemical
linkage to accomodate optical imaging [85]. It is claimed
that lactadherin has several advantages as a PS imaging
agent over annexin A5 and synaptotagmin I. It binds
membranes in a way that is proportional to PS content and
independent of both phosphatidylethanolamine and Ca
2?
[57]. The latter feature is, however, not a beneﬁt in vivo
because ionized extracellular Ca
2? levels ﬂuctuate around
1 mM which is more than sufﬁcient to promote binding of
annexin A5 and C2A-GST to PS expressing membranes.
The drawback of lactadherin is its posttranslational modi-
ﬁcation which precludes expression of functional lactadh-
erin recombinantly in an E. coli system.
The general picture of all imaging studies utilizing
annexin A5 and C2A-GST depicts feasibility of PS imag-
ing with non-invasive techniques including optical, radio-
nuclide and magnetic resonance imaging. Non-invasive PS
imaging can be employed to accomplish various goals
including understanding pathogenesis of cardiovascular
diseases such as heart failure [86] and atherosclerosis [87,
88] and evaluating therapeutic in vivo efﬁcacy of drugs
such as statins [89] and anti-cancer compounds [90, 91].
Most preclinical non-invasive PS imaging has been carried
out with radionuclide and magnetic resonance imaging.
Low tissue penetration of photons and autoﬂuorescence of
extracellular matrix components have been hampering
development of non-invasive optical imaging of PS.
Recently near-infrared ﬂuorescent (NIRF) probes and
ﬂuorescence mediated tomography (FMT) have been
developed rendering non-invasive optical imaging feasible
[92]. Second-generation annexin A5 has been coupled to
the NIRF probe Vivo-750 via thiol-chemistry and
employed successfully to quantify the anti-cancer effect of
cytotoxic compounds in a mouse cancer model using non-
invasive FMT (Fig. 3).
Fig. 3 Non-invasive PS-imaging of efﬁcacy of anti-cancer treatment.
Mice were implanted with HT-29 human colorectal adenocarcinoma
cells in both upper mammary fat pads, and tumors were allowed to
grow for 10 days. To assess the acute induction of apoptosis, animals
received a single IP injection of cyclophosphamide (CY; 170 mg/kg).
Animals were injected with second generation annexin A5 coupled to
Vivo 750 (annexin-Vivo 750, VisEn Medical) 24 h post-CY treatment
and imaged 2 h later by FMT 2500 (VisEn Medical) ﬂuorescence
tomography. Representative images of treated and untreated HT-29
mice were selected to reﬂect the mean group tumor ﬂuorescence
intensities. (a) 3D FMT images were acquired, and (b) the effects on
tumor ﬂuorescence and volume were assessed. Results indicate anti-
cancer efﬁcacy of CY in this model. Data and images courtesy of
VisEn Medical Inc., Bedford, MA, USA
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preclinical settings to the clinical arena. Availability of
clinical grade recombinant human annexin A5 for labeling
with Technetium (Tc
99m) and Single Photon Emission
Tomography (SPECT) has catalyzed clinical studies with
PS imaging in various patients to assess the signiﬁcance of
PS imaging for diagnosis and rapid evaluation of efﬁcacy
of therapy. Table 2 summarizes medical ﬁelds in which
Molecular Imaging of PS has been interrogated in pre-
clinical models and in patients. These studies show promise
for non-invasive imaging of PS to catalyze drug develop-
ment in preclinical settings and to support diagnosis and
evaluation efﬁcacy of treatment shortly after start of ther-
apy in the clinic.
PS as target for Targeted Drug Delivery (TDD)
strategies
TTD is a strategy the goal of which is to treat disease
effectively with minimal detrimental side-effects. Such
strategies are especially of importance to treatments in
which toxic substances are needed to combat disease. TDD
is based on the principle of Paul Ehrlich’s ‘Magic Bullet’
which in fact is a therapeutic compound that is guided to
the diseased lesion by a targeting function. The targeting
function can be an integral part of the therapeutic com-
pound or can be deliberately attached to the drug [93]. Cell
surface expressed PS is potentially an attractive target for
TDD considering the body of experience with PS as a
biomarker for Molecular Imaging [93, 94].
A wide range of diseases may beneﬁt from PS based
TDD strategies (see Table 2). In general PS is expressed by
dying and dead cells and cell remnants that accumulate in
diseased lesions such as atherosclerotic plaques and
tumours. In such lesions PS may function to accumulate PS
seeking ‘Magic Bullets’ and their therapeutic cargo, which
may for example encompass enzymes or cytotoxic sub-
stances. Recent experiments indicated that cells, which are
not committed to execute cell death, may also express PS
on their surface under speciﬁc conditions. Endothelial cells
of tumour vasculature for example express PS while being
alive [95]. Cardiomyocytes that have been submitted to
brief ischemia express PS before the apoptotic machinery
trespasses the point of no return [96]. These cells can be
targeted with therapeutic substances that either kill (tumour
endothelial cells) or rescue (stressed cardiomyocytes) the
PS expressing cell. Efﬁcient intracellular delivery of the
therapeutic substance is then necessary. Annexin A5 has
been shown to be internalized into the PS expressing cell as
a consequence of its property to form a 2-dimensional
lattice on the cell surface [44]. C2A-domain of synapto-
tagmin I and lactadherin have no reported property of
internalization into PS expressing cells.
Recent reports underscored feasibility and applicability
of the concept of PS targeting in TDD strategies. Annexin
A5 was used as vector to target coagulation and ﬁbrinolytic
enzymes to sites of PS expressing cells in the vasculature
[97–99]. These PS seeking ‘Magic bullets’ were con-
structed by molecular fusion [97, 99] or chemical coupling
[98] of annexin A5 and the enzyme. Annexin A5 by itself
integrates PS targeting and therapeutic function because
once bound to PS it blocks the inﬂammatory and immu-
nomodulatory activities of surface expressed PS [100].
Recently a homodimer of annexin A5 (diannexin) was
constructed with the purpose to prolong the blood
Table 2 Overview of preclinical and clinical imaging of PS for a variety of diseases and diagnostic purposes
Medical ﬁeld Diagnostic purpose of PS imaging References
Preclinical studies Clinical studies
Oncology Early assessment of efﬁcacy of therapy [90, 91, 111–114][ 115–118]
Prognosis of survival [119]
Cardiology Early diagnosis of heart failure [66, 86, 120–123][ 105]
Early assessment of cardiac toxicity [124]
Assessment of cardiac ischemia/reperfusion injury [125–127][ 104]
Vascular medicine Identiﬁcation of unstable atherosclerotic plaque [128, 129][ 130]
Orthopaedics Assessment of infection of prostheses [131]
Organ transplantation Allograft rejection [132][ 120, 133]
Gastroenterology Assessment of efﬁcacy of therapy in Crohn’s disease [134]
Neurology Identifying regions of cerebral injury [135, 136][ 137, 138]
Ophthalmology Assessment of retinal neurodegeneration [139, 140]
Autoimmune diseases Identifying regions of rheumatoid arthritis [141]
Metabolic diseases Measurement of b-cells apoptosis [142]
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of annexin A5 to attenuate ischemia/reperfusion induced
injury of organs [101].
PS has also been targeted with the antibody 3G4
(bavituximab), which binds with high afﬁnity to complexes
of b-2-glycoprotein I and PS. 3G4 was used therapeutically
as adjuvant therapy in viral infections in which PS surface
expression is essential to successful infection [26] and in
mouse models of cancer, which have tumour vasculature
with PS expressing endothelial cells [102, 103].
Diannexin and bavituximab are the ﬁrst PS-targeting
agents that have entered clinical trials to demonstrate
therapeutic activity in patients with kidney transplants,
chronic hepatic C virus and HIV and cancer (http://
clinicaltrials.gov).
Conclusion and future perspectives
PS is one of the most prominent and ubiquitous ﬁngerprints
ofcellsindiseasedtissues and,therefore,an attractive target
for Molecular Imaging and translation into clinical applica-
tions.Itsubiquityhasbothadvantagesanddisadvantages.On
the one hand a broad spectrum of diseases can be imaged
with a single compound but on the other hand ubiquity is
accompanied by reduced speciﬁcity requiring additional
diagnostic steps in order to differentiate. This is exempliﬁed
by reports that show that annexin A5 accumulation in the
heart of a patient can be the result of acute myocardial
infarction [104], ongoing heart failure [105], an intracardiac
tumour [106] and infection [107]. Speciﬁcity can be
increased by more accurate anatomic mapping of the sites
where annexin A5 accumulates for example by combining
imaging technologies such as SPECT/CT and PET/CT.
Development of imaging technology goes in the direction of
pin-pointing location of radioisotopes in the human body.
More accurate localisation of PS expressing cells will
increase the value of PS as a diagnostic biomarker.
PS ubiquity clearly affects TDD aiming at PS. As with
Molecular Imaging ubiquity has the advantage of broad
application of the PS-TDD concept. Differentiation can be
accomplished by tuning the therapeutic cargo of the PS
seeking ‘Magic Bullet’ for a speciﬁc disease. The disad-
vantage potentially resides within the side-effects of
treatment. No clear picture exists as yet about therapeutic
efﬁcacy in relation to undesired side-effects of PS seeking
‘Magic Bullets’. Future studies are necessary in order to
fully appreciate the value of PS as a target for TDD
strategies to treat diseases.
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